Aydin Huseynov
Stock Analyst at Ladenburg Thalmann
(0.59)
# 3,612
Out of 4,696 analysts
58
Total ratings
27.03%
Success rate
-30.54%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Aydin Huseynov
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MRKR Marker Therapeutics | Maintains: Buy | $11 → $19 | $3.89 | +388.43% | 2 | Oct 21, 2024 | |
| CRVS Corvus Pharmaceuticals | Maintains: Buy | $12 → $21 | $8.11 | +158.94% | 3 | Sep 16, 2024 | |
| CMPX Compass Therapeutics | Upgrades: Buy | $5 | $1.67 | +199.40% | 2 | Sep 16, 2024 | |
| ACRV Acrivon Therapeutics | Upgrades: Buy | $16 | $7.44 | +115.05% | 3 | Sep 16, 2024 | |
| CLDI Calidi Biotherapeutics | Initiates: Buy | $10 | $1.90 | +426.32% | 1 | Jun 27, 2024 | |
| CAPR Capricor Therapeutics | Maintains: Buy | $24 → $25 | $14.24 | +75.56% | 2 | May 14, 2024 | |
| ALRN Aileron Therapeutics | Maintains: Buy | $9 → $19 | $2.12 | +796.23% | 2 | Apr 18, 2024 | |
| SPRB Spruce Biosciences | Downgrades: Neutral | n/a | $0.43 | - | 3 | Mar 14, 2024 | |
| BDRX Biodexa Pharmaceuticals | Initiates: Buy | $200 | $4.45 | +4,394.38% | 1 | Feb 8, 2024 | |
| PMVP PMV Pharmaceuticals | Initiates: Buy | $7 | $1.57 | +345.86% | 1 | Dec 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $10 | $2.51 | +298.41% | 1 | Oct 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $3 | $0.18 | +1,525.14% | 1 | Sep 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $10 → $6 | $0.49 | +1,134.06% | 2 | Aug 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $20 → $10 | $2.27 | +340.53% | 3 | Jun 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $375 → $240 | $1.40 | +17,042.86% | 2 | May 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $8 → $14 | $0.85 | +1,555.82% | 2 | Apr 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Speculative Buy | $180 → $80 | $1.26 | +6,249.21% | 1 | Apr 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $20 | $5.93 | +237.27% | 1 | Mar 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $1.13 | - | 4 | Nov 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $1.05 | - | 2 | Aug 23, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $6 | $1.38 | +334.78% | 1 | Jul 27, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $21 | $4.71 | +345.86% | 1 | Jul 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $300 | $0.77 | +38,861.04% | 1 | May 6, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $37 | $5.96 | +520.81% | 1 | May 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $20 | $1.02 | +1,860.78% | 3 | Nov 8, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | n/a | $773.00 | - | 6 | Nov 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $89 | $72.49 | +22.78% | 2 | Jul 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Hold | n/a | $128.22 | - | 1 | Sep 30, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Speculative Buy | $1,000 | $1.58 | +63,191.14% | 1 | Jun 16, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $336 | $4.03 | +8,247.83% | 1 | May 21, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $18 | $6.34 | +183.91% | 1 | Mar 19, 2020 |
Marker Therapeutics
Oct 21, 2024
Maintains: Buy
Price Target: $11 → $19
Current: $3.89
Upside: +388.43%
Corvus Pharmaceuticals
Sep 16, 2024
Maintains: Buy
Price Target: $12 → $21
Current: $8.11
Upside: +158.94%
Compass Therapeutics
Sep 16, 2024
Upgrades: Buy
Price Target: $5
Current: $1.67
Upside: +199.40%
Acrivon Therapeutics
Sep 16, 2024
Upgrades: Buy
Price Target: $16
Current: $7.44
Upside: +115.05%
Calidi Biotherapeutics
Jun 27, 2024
Initiates: Buy
Price Target: $10
Current: $1.90
Upside: +426.32%
Capricor Therapeutics
May 14, 2024
Maintains: Buy
Price Target: $24 → $25
Current: $14.24
Upside: +75.56%
Aileron Therapeutics
Apr 18, 2024
Maintains: Buy
Price Target: $9 → $19
Current: $2.12
Upside: +796.23%
Spruce Biosciences
Mar 14, 2024
Downgrades: Neutral
Price Target: n/a
Current: $0.43
Upside: -
Biodexa Pharmaceuticals
Feb 8, 2024
Initiates: Buy
Price Target: $200
Current: $4.45
Upside: +4,394.38%
PMV Pharmaceuticals
Dec 27, 2023
Initiates: Buy
Price Target: $7
Current: $1.57
Upside: +345.86%
Oct 10, 2023
Initiates: Buy
Price Target: $10
Current: $2.51
Upside: +298.41%
Sep 22, 2023
Initiates: Buy
Price Target: $3
Current: $0.18
Upside: +1,525.14%
Aug 14, 2023
Maintains: Buy
Price Target: $10 → $6
Current: $0.49
Upside: +1,134.06%
Jun 5, 2023
Maintains: Buy
Price Target: $20 → $10
Current: $2.27
Upside: +340.53%
May 16, 2023
Maintains: Buy
Price Target: $375 → $240
Current: $1.40
Upside: +17,042.86%
Apr 28, 2023
Maintains: Buy
Price Target: $8 → $14
Current: $0.85
Upside: +1,555.82%
Apr 4, 2023
Maintains: Speculative Buy
Price Target: $180 → $80
Current: $1.26
Upside: +6,249.21%
Mar 7, 2023
Initiates: Buy
Price Target: $20
Current: $5.93
Upside: +237.27%
Nov 4, 2022
Downgrades: Neutral
Price Target: n/a
Current: $1.13
Upside: -
Aug 23, 2022
Downgrades: Neutral
Price Target: n/a
Current: $1.05
Upside: -
Jul 27, 2022
Initiates: Buy
Price Target: $6
Current: $1.38
Upside: +334.78%
Jul 13, 2022
Initiates: Buy
Price Target: $21
Current: $4.71
Upside: +345.86%
May 6, 2022
Initiates: Buy
Price Target: $300
Current: $0.77
Upside: +38,861.04%
May 2, 2022
Initiates: Buy
Price Target: $37
Current: $5.96
Upside: +520.81%
Nov 8, 2021
Upgrades: Buy
Price Target: $20
Current: $1.02
Upside: +1,860.78%
Nov 5, 2021
Downgrades: Hold
Price Target: n/a
Current: $773.00
Upside: -
Jul 20, 2021
Upgrades: Buy
Price Target: $89
Current: $72.49
Upside: +22.78%
Sep 30, 2020
Initiates: Hold
Price Target: n/a
Current: $128.22
Upside: -
Jun 16, 2020
Initiates: Speculative Buy
Price Target: $1,000
Current: $1.58
Upside: +63,191.14%
May 21, 2020
Initiates: Buy
Price Target: $336
Current: $4.03
Upside: +8,247.83%
Mar 19, 2020
Initiates: Buy
Price Target: $18
Current: $6.34
Upside: +183.91%